For older adults with CKD, initiation of a sodium-glucose cotransporter-2 (SGLT2) inhibitor is not associated with higher fracture risk compared with initiation of a dipeptidyl peptidase-4 (DPP-4) inhibitor, according to a study published in the Clinical Journal of the American Society of Nephrology. Researchers conducted a population-based cohort study to compare the incidence of fracture between new users of SGLT2 inhibitors and DPP-4 inhibitors. Inverse probability of treatment weighting based on propensity scores was used to balance the two groups of older adults (aged 66 and older) on indicators of baseline health. The 180- and 365-day cumulative incidence rates of fracture were compared between the groups. The weighted 180- and 365-day risks for a fragility fracture were not significantly different between the groups. There was no interaction observed between fracture risk and the category of eGFR.
- Business of Medicine
- Doctor’s Voice